Every October, we shine a spotlight on breast cancer during National Breast Cancer Awareness Month. Thanks to the remarkable innovations in AI (Artificial Intelligence), we have more reasons to raise awareness about advancements in mammography than ever before. AI-powered mammography is revolutionizing care for patients' breast health by finding cancers earlier, with greater accuracy and efficiency, standardizing assessments of breast density, and offering personalized evaluations for each patients’ risk of developing breast cancer in the next 1 – 2 years.

Improved Accuracy and Peace of Mind

Much like the significant s... Continue reading

At iCAD, we are recognizing the 2nd annual World Dense Breast Day today, a day that holds significant importance, not only for the women who may have dense breasts but for all of us dedicated to advancing breast health awareness and early cancer detection.

As we gather to mark this event, it's essential to reflect on how far we've come in the journey towards eradicating the shadows that cancer casts. At iCAD, we're committed to creating a world where cancer can't hide. And this year, we have some exciting developments to share, especially concerning one of the strongest and most prevalent breast cancer risk factors—dense brea... Continue reading

NASHUA, N.H., August 16, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada has issued a device license for ProFound Risk version 2.0, the latest version of iCAD's personalized 1-2 year breast cancer risk assessment solution.

"We are delighted to receive the device license from Health Canada for the latest version of ProFound Risk, marking a major milestone in our mission to help women worldwide know where and when breast cancer may be hiding," sa... Continue reading

Company to host conference call and webcast today at 4:30 PM ET

NASHUA, N.H. – August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023.

Highlights:

by Dana Brown, President and CEO of iCAD, Inc.

We’ve joined forces with Google Health once again to address two of the most pressing challenges in healthcare: the global radiologist shortage and significant disparities in healthcare.

Per our 20-year worldwide agreement, Google's AI technology will seamlessly integrate into our ProFound Breast Health Suite, including ProFound Detection, for use as an independent reader for breast cancer screening with 2D... Continue reading

Worldwide commercialization agreement offers potential to ease radiologist workload and reduce healthcare disparities for women

NASHUA, N.H., August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it signed an amendment to its development and commercialization agreement with Google Health, which will enable iCAD to integrate Google’s AI technology with its ProFound Breast Health Suite for 2D Mammography for use worldwide upon regulatory appr... Continue reading

NASHUA, N.H., July 31, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will release financial results for the second quarter of 2023 and host a conference call at 4:30 PM ET on Monday, August 14, 2023.

Earnings call details are as follows:

Domestic: 888-506-0062

International: 973-528-0011

Participant Access Code: 460678

Continue reading

Agreement positions iCAD as Radiology Partners’ breast AI provider, expanding potential for iCAD’s technology to reach millions of women in the U.S.

NASHUA, N.H., July 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a new strategic multi- year commercial agreement with Radiology Partners, the nation’s largest radiology practice through its owned and affiliated practices.

Under the agreement, which was executed on June 27, Radiology Partners selected iCAD as its provider of breast AI technologies deployed t... Continue reading

Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD’s Breast AI Suite helps her detect the breast cancers radiologists fear most

NASHUA, N.H., July 12, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound Insights, ProFound Impact” webinar series will feature Dr. Laura Dean, a renowned breast radiologist at the Cleveland Clinic. Titled “How Cleveland Clinic is Finding the Breast Cancers Radio... Continue reading

Company’s ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities

NASHUA, N.H., July 10, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it is showcasing its ProFound AI Suite of clinically proven solutions for breast cancer detection, density assessment, and short-term risk evaluation in booth #228 at the AHRA 2023 annual meeting, taking place July 9-12 in Ind... Continue reading

Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health outcomes

NASHUA, N.H., May 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its Breast AI Suite is a winner of the U.S. General Services Administration’s (GSA) “AI Healthcare Challenge” award. iCAD presented its portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competiti... Continue reading

Company to host conference call and webcast today at 4:30 PM ET 

NASHUA, N.H. – May 15, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023. 

Highlights:

98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published in Journal of Contemporary Brachytherapy

NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of non-melanoma skin cancer (NMSC). In the longest-term study of Xof... Continue reading

iCAD’s AI solution minimizes interval cancers and overcomes challenges associated with digital breast tomosynthesis

NASHUA, N.H., May 3, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world’s largest breast imaging conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7 in National Harbor, MD. Attendees are i... Continue reading

NASHUA, N.H., May 1, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, May 15, 2023.

Earnings call details are as follows:

Domestic: 877-545-0523

International: 973-528-0016

Continue reading

Kathy Schilling, MD, Boca Raton Regional Hospital, to discuss how ProFound AI helped nine dedicated breast radiologists find 23% more cancers, without increasing the rate of recalls

NASHUA, N.H., April 25, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound Insights, ProFound Impact” webinar series will feature Kathy Schilling, MD, Medical Director, Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital. The live event,... Continue reading

New research presented at American Roentgen Ray Society (ARRS) meeting continues to validate unique value iCAD’s deep-learning breast AI solution offers to clinicians and patients

NASHUA, N.H., April 20, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies. One... Continue reading

Eric Lonnqvist as Chief Financial Officer, Vasu Avadhanula as Chief Product Officer, and Michelle Strong as Chief Operations Officer bolster the Company’s executive leadership team and accelerate the Company’s growth strategies

NASHUA, N.H., April 17, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula as Chief Pro... Continue reading

ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family history of breast cancer

NASHUA, N.H., April 4, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new clinical evidence published in the Journalof Clinical Oncology found ProFound AI® Risk for 2D Mammography is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model, for both short-term... Continue reading

     Strategy focused on profitability by end of 2024, using current cash on hand

New leadership to host conference call and webcast today at 4:30 PM ET

NASHUA, N.H. – March 28, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the twelve months ended December 31, 2022.

Highlig... Continue reading